5-Lipoxygenase and 5-lipoxygenase-activating protein gene polymorphisms, dietary linoleic acid, and risk for breast cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 10, 2008, Pages 2748-2754

  Wang, Jun ^a,f   John, Esther M ^b,c,d   Ingles, Sue Ann ^e  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NORTHERN CALIFORNIA CANCER CENTER   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d STANFORD CANCER INSTITUTE   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; LINOLEIC ACID;

ADULT; AFRICAN AMERICAN; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CASE CONTROL STUDY; CAUCASIAN; CONTROLLED STUDY; DIETARY INTAKE; ETHNIC DIFFERENCE; FAT INTAKE; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENOTYPE; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MICROSATELLITE MARKER; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED STATES; VARIABLE NUMBER OF TANDEM REPEAT;

AFRICAN AMERICANS; ARACHIDONATE 5-LIPOXYGENASE; BREAST NEOPLASMS; CARRIER PROTEINS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HISPANIC AMERICANS; HUMANS; LINOLEIC ACID; MEMBRANE PROTEINS; MIDDLE AGED; POLYMORPHISM, GENETIC; QUESTIONNAIRES; REGISTRIES; RISK FACTORS; SAN FRANCISCO; TANDEM REPEAT SEQUENCES;

EID: 54249118807     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0439     Document Type: Article

References (39)

1. Fay MP, Freedman LS, Clifford CK, Midthune DN. Effect of different types and amounts of fat on the development of mammary tumors in rodents: a review. Cancer Res 1997;57:3979-88.
2. Natarajan R, Nadler J. Role of lipoxygenases in breast cancer. Front Biosci 1998;3:E81-8.
3. Shureiqi I, Lippman SM. Lipoxygenase modulation to reverse carcinogenesis. Cancer Res 2001;61:6307-12.
4. Rubin P, Mollison KW. Pharmacotherapy of diseases mediated by 5-lipoxygenase pathway eicosanoids. Prostaglandins Other Lipid Mediat 2007;83:188-97.
5. Avis IM, Jett M, Boyle T, et al. Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J Clin Invest 1996;97:806-13.
6. Soumaoro LT, Iida S, Uetake H, et al. Expression of 5-lipoxygenase in human colorectal cancer. World J Gastroenterol 2006;12:6355-60.
7. Ye YN, Wu WK, Shin VY, Bruce IC, Wong BC, Cho CH. Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke. Carcinogenesis 2005;26:827-34.
8. Ghosh J, Myers CE. Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase. Biochem Biophys Res Commun 1997;235:418-23.
9. Sundaram S, Ghosh J. Expression of 5-oxoETE receptor in prostate cancer cells: critical role in survival. Biochem Biophys Res Commun 2006;339:93-8.
10. Faronato M, Muzzonigro G, Milanese G, et al. Increased expression of 5-lipoxygenase is common in clear cell renal cell carcinoma. Histol Histopathol 2007;22:1109-18.
11. Hayashi T, Nishiyama K, Shirahama T. Inhibition of 5-lipoxygenase pathway suppresses the growth of bladder cancer cells. Int J Urol 2006;13:1086-91.
12. Tong WG, Ding XZ, Talamonti MS, Bell RH, Adrian TE. LTB4 stimulates growth of human pancreatic cancer cells via MAPK and PI-3 kinase pathways. Biochem Biophys Res Commun 2005;335:949-56.
13. Hennig R, Grippo P, Ding XZ, et al. 5-Lipoxygenase, a marker for early pancreatic intraepithelial neoplastic lesions. Cancer Res 2005;65:6011-6.
14. Hoque A, Lippman SM, Wu TT, et al. Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention. Carcinogenesis 2005.
15. Chen X, Wang S, Wu N, et al. Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis. Clin Cancer Res 2004;10:6703-9.
16. Rioux N, Castonguay A. Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents. Carcinogenesis 1998;19:1393-400.
17. Ding XZ, Tong WG, Adrian TE. Cyclooxygenases and lipoxygenases as potential targets for treatment of pancreatic cancer. Pancreatology 2001;1:291-9.
18. Nie D, Tang K, Szekeres K, Li L, Honn KV. Eicosanoid regulation of angiogenesis in human prostate carcinoma and its therapeutic implications. Ann N Y Acad Sci 2000;905:165-76.
19. Jiang WG, Douglas-Jones A, Mansel RE. Levels of expression of lipoxygenases and cyclooxygenase-2 in human breast cancer. Prostaglandins Leukot Essent Fatty Acids 2003;69:275-81.
20. Jiang WG, Douglas-Jones AG, Mansel RE. Aberrant expression of 5-lipoxygenase-activating protein (5-LOXAP) has prognostic and survival significance in patients with breast cancer. Prostaglandins Leukot Essent Fatty Acids 2006;74:125-34.
21. Avis I, Hong SH, Martinez A, et al. Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions. FASEB J 2001;15:2007-9.
22. Kim JH, Hubbard NE, Ziboh V, Erickson KL. Attenuation of breast tumor cell growth by conjugated linoleic acid via inhibition of 5-lipoxygenase activating protein. Biochim Biophys Acta 2005;1736:244-50.
23. Poeckel D, Niedermeyer TH, Pham HT, et al. Inhibition of human 5-lipoxygenase and anti-neoplastic effects by 2-amino-1,4-benzoquinones. Med Chem 2006;2:591-5.
24. Flavin DF. A lipoxygenase inhibitor in breast cancer brain metastases. J Neurooncol 2007;82:91-3.
25. Boyd NF, Stone J, Vogt KN, Connelly BS, Martin LJ, Minkin S. Dietary fat and breast cancer risk revisited: a meta-analysis of the published literature. Br J Cancer 2003;89:1672-85.
26. John EM, Horn-Ross PL, Koo J. Lifetime physical activity and breast cancer risk in a multiethnic population: the San Francisco Bay area breast cancer study. Cancer Epidemiol Biomarkers Prev 2003;12:1143-52.
27. John EM, Schwartz GG, Koo J, Wang W, Ingles SA. Sun exposure, vitamin D receptor gene polymorphisms, and breast cancer risk in a multiethnic population. Am J Epidemiol 2007;166:1409-19.
28. Block G, Hartman AM, Dresser CM, Carroll MD, Gannon J, Gardner L. A data-based approach to diet questionnaire design and testing. Am J Epidemiol 1986;124:453-69.
29. Horn-Ross PL. Assessing phytoestrogen exposure via a food-frequency questionnaire. Cancer Causes Control 2001;12:477-8.
30. Ovcharenko I, Nobrega MA, Loots GG, Stubbs L. ECR Browser: a tool for visualizing and accessing data from comparisons of multiple vertebrate genomes. Nucleic Acids Res 2004;32:W280-6.
31. Sayers I, Barton S, Rorke S, et al. Promoter polymorphism in the 5-lipoxygenase (ALOX5) and 5-lipoxygenase-activating protein (ALOX5AP) genes and asthma susceptibility in a Caucasian population. Clin Exp Allergy 2003;33:1103-10.
32. Dwyer JH, Allayee H, Dwyer KM, et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 2004;350:29-37.
33. Koshino T, Takano S, Kitani S, et al. Novel polymorphism of the 5-lipoxygenase activating protein (FLAP) promoter gene associated with asthma. Mol Cell Biol Res Commun 1999;2:32-5.
34. Helgadottir A, Manolescu A, Thorleifsson G, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004;36:233-9.
35. Goodman JE, Bowman ED, Chanock SJ, Alberg AJ, Harris CC. Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX) polymorphisms and colon cancer risk. Carcinogenesis 2004.
36. In KH, Asano K, Beier D, et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest 1997;99:1130-7.
37. Silverman ES, Du J, De Sanctis GT, et al. Egr-1 and Sp1 interact functionally with the 5-lipoxygenase promoter and its naturally occurring mutants. Am J Respir Cell Mol Biol 1998;19:316-23.
38. Uhl J, Klan N, Rose M, Entian KD, Werz O, Steinhilber D. The 5-lipoxygenase promoter is regulated by DNA methylation. J Biol Chem 2002;277:4374-9.
39. Kantarci A, Van Dyke TE. Lipoxins in chronic inflammation. Crit Rev Oral Biol Med 2003;14:4-12.